IPOs abound in the time of coronavirus, as Forma Therapeutics pencils in $150M Nasdaq debut

IPOs abound in the time of coronavirus, as Forma Therapeutics pencils in $150M Nasdaq debut

Source: 
Endpoints
snippet: 

The IPO engine is thriving, never mind the rampage of the coronavirus crisis on R&D timelines.

On Friday, along with synthetic lethality-focused biotech Repare Therapeutics, another Bristol Myers partner Forma Therapeutics also unveiled its plans to vault on to the Nasdaq — penciling in a target of $150 million.